中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2014年
32期
24-25
,共2页
恩替卡韦%乙型肝炎肝硬化%临床研究
恩替卡韋%乙型肝炎肝硬化%臨床研究
은체잡위%을형간염간경화%림상연구
Entecavir%Hepatitis B cirrhosis%Clinical study
目的：研究恩替卡韦治疗乙型肝炎肝硬化的临床效果。方法选取2012年4月＿2013年4月该院收治的100例乙型肝炎肝硬化患者,随机等分为对照组与观察组。对照组在常规治疗的基础上加用拉米夫定,观察组在常规治疗的基础上加用恩替卡韦,比较两组患者治疗前后肝功能指标﹙ALT﹑AST﹑TBIL﹑ALB﹚及肝纤维化指标﹙HA﹑LN﹑IV-C﹚变化情况。结果观察组肝功能指标﹙ALT﹑AST﹑TBIL﹑ALB﹚均有改善,治疗后ALT平均水平﹙50.12±14.45﹚U/L,AST平均水平﹙45.32±12.26﹚U/L, TBIL平均水平﹙21.48±5.74﹚umol/L,ALB平均水平﹙37.86±3.93﹚g/L,较对照组差异有统计学意义﹙P<0.05﹚；观察组肝纤维化指标﹙HA﹑LN﹑IV-C﹚均有改善,治疗后HA平均水平﹙15.48±3.46﹚ng/L,LN平均水平﹙56.92±14.05﹚ng/L,IV-C平均水平﹙83.56±27.38﹚,较对照组差异有统计学意义﹙P<0.05﹚。结论恩替卡韦治疗乙型肝炎肝硬化有助于改善患者肝功能及肝纤维化,临床上值得推广。
目的：研究恩替卡韋治療乙型肝炎肝硬化的臨床效果。方法選取2012年4月＿2013年4月該院收治的100例乙型肝炎肝硬化患者,隨機等分為對照組與觀察組。對照組在常規治療的基礎上加用拉米伕定,觀察組在常規治療的基礎上加用恩替卡韋,比較兩組患者治療前後肝功能指標﹙ALT﹑AST﹑TBIL﹑ALB﹚及肝纖維化指標﹙HA﹑LN﹑IV-C﹚變化情況。結果觀察組肝功能指標﹙ALT﹑AST﹑TBIL﹑ALB﹚均有改善,治療後ALT平均水平﹙50.12±14.45﹚U/L,AST平均水平﹙45.32±12.26﹚U/L, TBIL平均水平﹙21.48±5.74﹚umol/L,ALB平均水平﹙37.86±3.93﹚g/L,較對照組差異有統計學意義﹙P<0.05﹚；觀察組肝纖維化指標﹙HA﹑LN﹑IV-C﹚均有改善,治療後HA平均水平﹙15.48±3.46﹚ng/L,LN平均水平﹙56.92±14.05﹚ng/L,IV-C平均水平﹙83.56±27.38﹚,較對照組差異有統計學意義﹙P<0.05﹚。結論恩替卡韋治療乙型肝炎肝硬化有助于改善患者肝功能及肝纖維化,臨床上值得推廣。
목적：연구은체잡위치료을형간염간경화적림상효과。방법선취2012년4월＿2013년4월해원수치적100례을형간염간경화환자,수궤등분위대조조여관찰조。대조조재상규치료적기출상가용랍미부정,관찰조재상규치료적기출상가용은체잡위,비교량조환자치료전후간공능지표﹙ALT﹑AST﹑TBIL﹑ALB﹚급간섬유화지표﹙HA﹑LN﹑IV-C﹚변화정황。결과관찰조간공능지표﹙ALT﹑AST﹑TBIL﹑ALB﹚균유개선,치료후ALT평균수평﹙50.12±14.45﹚U/L,AST평균수평﹙45.32±12.26﹚U/L, TBIL평균수평﹙21.48±5.74﹚umol/L,ALB평균수평﹙37.86±3.93﹚g/L,교대조조차이유통계학의의﹙P<0.05﹚；관찰조간섬유화지표﹙HA﹑LN﹑IV-C﹚균유개선,치료후HA평균수평﹙15.48±3.46﹚ng/L,LN평균수평﹙56.92±14.05﹚ng/L,IV-C평균수평﹙83.56±27.38﹚,교대조조차이유통계학의의﹙P<0.05﹚。결론은체잡위치료을형간염간경화유조우개선환자간공능급간섬유화,림상상치득추엄。
Objective To study the clinical effect of entecavir in the treatment of hepatitis B cirrhosis. Methods 100 cases with hepatitis B cirrhosis admitted in our hospital from April 2012 to April 2013 were randomly and equally divided into the control group and the observation group. Based on the conventional treatment, the control group was treated by lamivudine, and the obser_vation group was treated by entecavir. The changes of liver function indexes(ALT, AST, TBIL, ALB) and liver fibrosis indexes(HA, LN, IV-C) were compared between the two groups before and after treatment. Results The liver function indexes(ALT,AST,TBIL, ALB) of the observation group were improved, after treatment, the average level of ALT was (50.12±14.45) U/L, and that of AST was (45.32±12.26) U/L, that of TBIL was (21.48±5.74) umol/L, that of ALB was (37.86±3.93) g/L, compared with that of the control group, respectively, the differences between the groups were statistically significant(P<0.05);the liver fibrosis indexes(HA, LN, IV-C) were improved, after treatment, the average level of HA was (15.48±3.46) ng/L, and that of LN was (56.92±14.05) ng/L, that of IV-C was (83.56±27.38), compared with that of the control group, respectively, the differences between the groups were statistical_ly significant (P<0.05). Conclusion Entecavir for the treatment of hepatitis B cirrhosis is helpful to improve the liver function and liver fibrosis of the patients, which is worth promoting clinically.
